While Conmed Corp has overperformed by 2.01%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CNMD fell by -25.26%, with highs and lows ranging from $78.19 to $46.00, whereas the simple moving average fell by -17.01% in the last 200 days.
On June 12, 2025, Needham Downgraded Conmed Corp (NYSE: CNMD) to Hold. A report published by Stifel on April 28, 2025, Downgraded its rating to ‘Hold’ for CNMD. JP Morgan also Downgraded CNMD shares as ‘Neutral’, setting a target price of $70 on the company’s shares in a report dated February 06, 2025. Needham Reiterated the rating as Buy on February 01, 2024, but set its price target from $119 to $129. CL King initiated its ‘Buy’ rating for CNMD, as published in its report on May 22, 2023. KeyBanc Capital Markets’s report from March 27, 2023 suggests a price prediction of $124 for CNMD shares, giving the stock a ‘Overweight’ rating. Wells Fargo also rated the stock as ‘Equal Weight’.
Analysis of Conmed Corp (CNMD)
Investors in Conmed Corp will get a return regardless of how the company performs over the next quarter since the company’s dividend stands at $0.80 per share. Further, the quarter-over-quarter increase in sales is 3.72%, showing a positive trend in the upcoming months.
One of the most important indicators of Conmed Corp’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 12.96% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.00, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CNMD is recording 421.85K average volume. On a monthly basis, the volatility of the stock is set at 3.71%, whereas on a weekly basis, it is put at 3.84%, with a gain of 3.21% over the past seven days. Furthermore, long-term investors anticipate a median target price of $61.00, showing growth from the present price of $51.15, which can serve as yet another indication of whether CNMD is worth investing in or should be passed over.
How Do You Analyze Conmed Corp Shares?
The Medical Devices market is dominated by Conmed Corp (CNMD) based in the USA. When comparing Conmed Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 14.44, there is a growth in quarterly earnings of -28.40%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.81%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 113.30% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
